KAIROS PHARMA LTD (KAPA) Stock Price, Forecast & Analysis
NYSEARCA:KAPA • US48301N1046
KAPA Key Statistics, Chart & Performance
The current stock price of KAPA is 0.5721 USD. In the past month the price decreased by -20.54%. In the past year, price decreased by -51.92%.
KAPA Technical Analysis
KAPA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KAPA. No worries on liquidiy or solvency for KAPA as it has an excellent financial health rating, but there are worries on the profitability.
KAPA Financial Highlights
Over the last trailing twelve months KAPA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by -33.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.76% | ||
| ROE | -66.05% | ||
| Debt/Equity | 0 |
KAPA Forecast & Estimates
9 analysts have analysed KAPA and the average price target is 8.5 USD. This implies a price increase of 1385.75% is expected in the next year compared to the current price of 0.5721.
KAPA Ownership
KAPA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KAPA
Company Profile
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The company is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Company Info
KAIROS PHARMA LTD
2355 Westwood Blvd. #139
Los Angeles CALIFORNIA US
Employees: 3
Phone: 18184045541
KAIROS PHARMA LTD / KAPA FAQ
What does KAIROS PHARMA LTD do?
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The company is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
What is the stock price of KAIROS PHARMA LTD today?
The current stock price of KAPA is 0.5721 USD. The price increased by 2.58% in the last trading session.
Does KAIROS PHARMA LTD pay dividends?
KAPA does not pay a dividend.
What is the ChartMill technical and fundamental rating of KAPA stock?
KAPA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for KAPA stock?
KAIROS PHARMA LTD (KAPA) currently has 3 employees.
What is the outstanding short interest for KAIROS PHARMA LTD?
The outstanding short interest for KAIROS PHARMA LTD (KAPA) is 1.19% of its float.